PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV

Mounjaro (Tirzepatide) Vs Ozempic (Semaglutide) For Weight Loss & Diabetes Management

4:58Jul 2022

Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

A pharmacist named the speaker compares Mounjaro (tirzepatide) with Ozempic (semaglutide) for diabetes management and weight loss. He says early data suggests Mounjaro performs better on both, and he explains the reason he sees for that.

Published by HealthRX on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

He walks through a head-to-head comparison in people with type 2 diabetes who were also taking metformin. According to the video, Mounjaro at 5, 10 and 15 milligrams was compared with Ozempic at 1 milligram. He says Mounjaro lowered A1C more in every case from an average starting level of 8.3 percent, and that even the lowest Mounjaro dose beat Ozempic 1 milligram. For weight, he cites a 40-week study in which people on about 5 milligrams of Mounjaro lost about 17 pounds, compared with 13 pounds on Ozempic 1 milligram. He cautions that Mounjaro is not yet approved for weight loss and that these figures come from diabetes trials.

The speaker attributes the difference to how the drugs work. He explains that both mimic incretin hormones, but Mounjaro stimulates both GIP and GLP-1 receptors, while Ozempic, Trulicity, Byetta and Bydureon stimulate only GLP-1. He says GIP accounts for about two thirds of the insulin-raising and glucagon-lowering action. He closes by saying people doing well on Ozempic should stay on it, and those not reaching their goals could ask their doctor whether Mounjaro is an option.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:32 The speaker says the initial data points to Mounjaro being better than Ozempic for both diabetes management and weight loss.
  2. 1:03 In the diabetes comparison, Mounjaro at 5, 10 and 15 milligrams lowered A1C more than Ozempic at 1 milligram from a starting average of 8.3 percent.
  3. 1:33 He notes Mounjaro is not yet approved for weight loss, and the weight data come from diabetes trials.
  4. 2:03 In a 40-week study, people on about 5 milligrams of Mounjaro lost about 17 pounds versus 13 pounds on Ozempic 1 milligram.
  5. 3:04 He explains Mounjaro activates both GIP and GLP-1 receptors, while Ozempic and similar drugs activate only GLP-1.
  6. 4:35 He advises staying on Ozempic if it works, and talking with a doctor about Mounjaro if goals are not being met.

Key moments

Tap one to play from there.

  1. 0:00 Intro
  2. 0:53 Data
  3. 1:49 Weight Loss
  4. 3:04 GIP GLp1

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Ozempic, Mounjaro, semaglutide and tirzepatide

Questions this video answers

Is Mounjaro more effective than Ozempic for lowering A1C?

According to the pharmacist, Mounjaro at 5, 10 and 15 milligrams lowered A1C more than Ozempic at 1 milligram in a head-to-head comparison. The participants had type 2 diabetes, took metformin and started at an average A1C of 8.3 percent. He says even the lowest Mounjaro dose outperformed Ozempic 1 milligram.

How much weight did people lose on Mounjaro compared with Ozempic?

He cites a 40-week study in which people taking about 5 milligrams of Mounjaro lost about 17 pounds, while those on Ozempic 1 milligram lost 13 pounds. He adds that Mounjaro is not yet approved for weight loss and the data come from diabetes trials.

Why would Mounjaro work better than Ozempic?

The speaker says Mounjaro stimulates both GIP and GLP-1 receptors, while Ozempic, Trulicity, Byetta and Bydureon stimulate only GLP-1. He says GIP accounts for about two thirds of the insulin-boosting and glucagon-lowering action, so Mounjaro hits the stronger receptor as well.

Should I switch from Ozempic to Mounjaro?

The pharmacist says that if Ozempic is working for you, you should stay on it. He suggests that if you and your doctor are not seeing the results you want, it may be worth asking whether Mounjaro is the right choice.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • Mounjaro vs Ozempic, and the trial everyone quotes about it

    Mounjaro is tirzepatide and Ozempic is semaglutide: different molecules, not two brands of the same drug. Both are approved for type 2 diabetes, and the weight-loss versions are Zepbound and Wegovy. In the one head-to-head trial, SURMOUNT-5, tirzepatide produced 20.2% mean body-weight loss at 72 weeks against semaglutide's 13.7%. The detail almost every page omits: that trial dosed semaglutide to 2.4 mg in people without diabetes, which is the Wegovy range. Ozempic tops out at 2 mg. The famous result did not test Ozempic's dose range.

  • Mounjaro for weight loss, and why Zepbound exists

    Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is the same molecule from the same maker, approved for weight management, and it goes to the same 15 mg. So unlike Ozempic and Wegovy, there is no dose ceiling pushing you from one to the other: the reason people move is coverage and cash price, not strength. Using Mounjaro for weight is off-label and a prescriber's decision. In the one head-to-head trial, tirzepatide beat semaglutide, 20.2% mean body-weight loss at 72 weeks against 13.7%.

  • Mounjaro side effects: the label's numbers by dose, the low blood sugar risk, and how tirzepatide compares at weight-loss doses

    On Mounjaro's own label, the common side effects are stomach ones and they rise with the dose: nausea in 12, 15 and 18 percent of people at 5, 10 and 15 mg against 4 percent on placebo, diarrhea 12 to 17 against 9, and any gastrointestinal reaction in 37 to 44 percent against 20. Most of it happens while the dose is being raised and fades. Low blood sugar is rare on Mounjaro alone and is mainly a risk when it is added to insulin or a sulfonylurea. Below: the full table, the rare warnings, and why Zepbound's numbers for the same molecule look higher.

Next steps

Ozempic prices

Insurance

Find more like it

Dose changeWeigh-in and resultsExercise and strengthHow it worksThe trials

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV